Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Halogen-substituted anthranilic acid derivatives provide a novel chemical platform for androgen receptor antagonists.

Roell D, Rösler TW, Hessenkemper W, Kraft F, Hauschild M, Bartsch S, Abraham TE, Houtsmuller AB, Matusch R, van Royen ME, Baniahmad A.

J Steroid Biochem Mol Biol. 2019 Apr;188:59-70. doi: 10.1016/j.jsbmb.2018.12.005. Epub 2019 Jan 4.

PMID:
30615932
2.

The Effect of Adding Dexmedetomidine as an Adjuvant to Lidocaine in Forearm Fracture Surgeries by Supraclavicular Block Procedure Under Ultrasound-Guided.

Akhondzadeh R, Rashidi M, Gousheh M, Olapour A, Baniahmad A.

Anesth Pain Med. 2018 Jul 25;8(4):e74355. doi: 10.5812/aapm.74355. eCollection 2018 Aug.

3.

A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer.

Warren AY, Massie CE, Watt K, Luko K, Orafidiya F, Selth LA, Mohammed H, Chohan BS, Menon S, Baridi A, Zhao W, Escriu C, Pungsrinont T, D'Santos C, Yang X, Taylor C, Qureshi A, Zecchini VR, Shaw GL, Dehm SM, Mills IG, Carroll JS, Tilley WD, McEwan IJ, Baniahmad A, Neal DE, Asim M.

Oncogene. 2019 Feb;38(7):1136-1150. doi: 10.1038/s41388-018-0501-z. Epub 2018 Sep 20.

4.

Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.

Lakshmana G, Baniahmad A.

Int J Cancer. 2019 Apr 15;144(8):1775-1779. doi: 10.1002/ijc.31818. Epub 2018 Nov 4. Review.

PMID:
30125354
5.

Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer.

Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, Baridi A, Warren AY, Zhao W, Ogris C, McDuffus LA, Mascalchi P, Shaw G, Dev H, Wadhwa K, Wijnhoven P, Forment JV, Lyons SR, Lynch AG, O'Neill C, Zecchini VR, Rennie PS, Baniahmad A, Tavaré S, Mills IG, Galanty Y, Crosetto N, Schultz N, Neal D, Helleday T.

Nat Commun. 2017 Aug 29;8(1):374. doi: 10.1038/s41467-017-00393-y.

6.

Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.

Colditz J, Rupf B, Maiwald C, Baniahmad A.

Mol Cell Biochem. 2016 Oct;421(1-2):139-47. doi: 10.1007/s11010-016-2794-y. Epub 2016 Aug 25.

PMID:
27562825
7.

The activation of OR51E1 causes growth suppression of human prostate cancer cells.

Maßberg D, Jovancevic N, Offermann A, Simon A, Baniahmad A, Perner S, Pungsrinont T, Luko K, Philippou S, Ubrig B, Heiland M, Weber L, Altmüller J, Becker C, Gisselmann G, Gelis L, Hatt H.

Oncotarget. 2016 Jul 26;7(30):48231-48249. doi: 10.18632/oncotarget.10197.

8.

A novel crosstalk between the tumor suppressors ING1 and ING2 regulates androgen receptor signaling.

Esmaeili M, Pungsrinont T, Schaefer A, Baniahmad A.

J Mol Med (Berl). 2016 Oct;94(10):1167-1179. Epub 2016 Jun 16.

PMID:
27305909
9.

The Evolution of COP9 Signalosome in Unicellular and Multicellular Organisms.

Barth E, Hübler R, Baniahmad A, Marz M.

Genome Biol Evol. 2016 May 2;8(4):1279-89. doi: 10.1093/gbe/evw073.

10.

The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells.

Esmaeili M, Jennek S, Ludwig S, Klitzsch A, Kraft F, Melle C, Baniahmad A.

J Mol Cell Biol. 2016 Jun;8(3):207-20. doi: 10.1093/jmcb/mjw007. Epub 2016 Mar 18.

PMID:
26993046
11.

Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.

Asim M, Massie CE, Orafidiya F, Pértega-Gomes N, Warren AY, Esmaeili M, Selth LA, Zecchini HI, Luko K, Qureshi A, Baridi A, Menon S, Madhu B, Escriu C, Lyons S, Vowler SL, Zecchini VR, Shaw G, Hessenkemper W, Russell R, Mohammed H, Stefanos N, Lynch AG, Grigorenko E, D'Santos C, Taylor C, Lamb A, Sriranjan R, Yang J, Stark R, Dehm SM, Rennie PS, Carroll JS, Griffiths JR, Tavaré S, Mills IG, McEwan IJ, Baniahmad A, Tilley WD, Neal DE.

J Natl Cancer Inst. 2015 Dec 11;108(5). doi: 10.1093/jnci/djv371. Print 2016 May.

12.

Inhibition of the Androgen Receptor by Antiandrogens in Spinobulbar Muscle Atrophy.

Baniahmad A.

J Mol Neurosci. 2016 Mar;58(3):343-7. doi: 10.1007/s12031-015-0681-8. Epub 2015 Nov 12. Review.

PMID:
26563449
13.

Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer.

Perner S, Cronauer MV, Schrader AJ, Klocker H, Culig Z, Baniahmad A.

Oncotarget. 2015 Nov 3;6(34):35542-55. doi: 10.18632/oncotarget.4689. Review.

14.

Docosahexaenoic acid inhibits the growth of hormone-dependent prostate cancer cells by promoting the degradation of the androgen receptor.

Hu Z, Qi H, Zhang R, Zhang K, Shi Z, Chang Y, Chen L, Esmaeili M, Baniahmad A, Hong W.

Mol Med Rep. 2015 Sep;12(3):3769-3774. doi: 10.3892/mmr.2015.3813. Epub 2015 May 21.

PMID:
25997493
15.

Why do we need to age?

Baniahmad A.

Horm Mol Biol Clin Investig. 2013 Dec;16(1):3-5. doi: 10.1515/hmbci-2013-0030.

PMID:
25436741
16.

Special issue on hormones and ageing.

Baniahmad A, Tresguerres JA, Zouboulis CC.

Horm Mol Biol Clin Investig. 2013 Dec;16(1):1-2. doi: 10.1515/hmbci-2013-0064. No abstract available.

PMID:
25436740
17.

Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway.

Roediger J, Hessenkemper W, Bartsch S, Manvelyan M, Huettner SS, Liehr T, Esmaeili M, Foller S, Petersen I, Grimm MO, Baniahmad A.

Mol Cancer. 2014 Sep 12;13:214. doi: 10.1186/1476-4598-13-214.

18.

A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells.

Hessenkemper W, Roediger J, Bartsch S, Houtsmuller AB, van Royen ME, Petersen I, Grimm MO, Baniahmad A.

Mol Endocrinol. 2014 Nov;28(11):1831-40. doi: 10.1210/me.2014-1170. Epub 2014 Sep 9.

19.

Atypical polycystic ovary syndrome--a genetic analysis.

Scholten M, Vilser C, Weise A, Baniahmad A.

Exp Clin Endocrinol Diabetes. 2015 Jan;123(1):55-60. doi: 10.1055/s-0034-1387735. Epub 2014 Aug 22.

PMID:
25148265
20.

Novel Nor-Homo- and Spiro-Oxetan- Steroids Target the Human Androgen Receptor and Act as Antiandrogens.

Thiele M, Rabe S, Hessenkemper W, Roell D, Bartsch S, Kraft F, Abraham TE, Houtsmuller AB, van Royen ME, Giannis A, Baniahmad A.

Curr Med Chem. 2015;22(9):1156-1167. doi: 10.2174/0929867321666140601164240. Epub 2014 Jun 1.

PMID:
24934352
21.

Targeting heat shock proteins in prostate cancer.

Hessenkemper W, Baniahmad A.

Curr Med Chem. 2013;20(22):2731-40. Review.

PMID:
23521679
22.

The corepressor activity of Alien is controlled by CREB-binding protein/p300.

Eckey M, Kraft F, Kob R, Escher N, Asim M, Fischer H, Fritsche MK, Melle C, Baniahmad A.

FEBS J. 2013 Apr;280(8):1861-8. doi: 10.1111/febs.12211. Epub 2013 Mar 18.

23.

Computational and functional analysis of the androgen receptor antagonist atraric acid and its derivatives.

Papaioannou M, Söderholm AA, Hong W, Dai Y, Roediger J, Roell D, Thiele M, Nyrönen TH, Baniahmad A.

Anticancer Agents Med Chem. 2013 Jun;13(5):801-10. Review.

PMID:
23194423
24.

Chaperones for proper androgen action - a plethora of assistance to androgen receptor function.

Hessenkemper W, Baniahmad A.

Horm Mol Biol Clin Investig. 2012 Oct;11(1):321-8. doi: 10.1515/hmbci-2012-0031.

PMID:
25436691
25.

Benign prostate hyperplasia meets liver x receptor.

Baniahmad A.

Endocrinology. 2012 Aug;153(8):3558-60. doi: 10.1210/en.2012-1474. Epub 2012 Jun 25. No abstract available.

PMID:
22733967
26.

Epigenetic involvement of Alien/ESET complex in thyroid hormone-mediated repression of E2F1 gene expression and cell proliferation.

Hong W, Li J, Wang B, Chen L, Niu W, Yao Z, Baniahmad A.

Biochem Biophys Res Commun. 2011 Dec 2;415(4):650-5. doi: 10.1016/j.bbrc.2011.10.130. Epub 2011 Nov 3.

PMID:
22079090
27.

Sodium butyrate induces cellular senescence in neuroblastoma and prostate cancer cells.

Lorenz V, Hessenkemper W, Rödiger J, Kyrylenko S, Kraft F, Baniahmad A.

Horm Mol Biol Clin Investig. 2011 Oct 1;7(1):265-72. doi: 10.1515/HMBCI.2011.020.

PMID:
25961265
28.

Ligand-dependent corepressor acts as a novel androgen receptor corepressor, inhibits prostate cancer growth, and is functionally inactivated by the Src protein kinase.

Asim M, Hafeez BB, Siddiqui IA, Gerlach C, Patz M, Mukhtar H, Baniahmad A.

J Biol Chem. 2011 Oct 28;286(43):37108-17. doi: 10.1074/jbc.M111.292771. Epub 2011 Aug 19.

29.

Detection of ligand-selective interactions of the human androgen receptor by SELDI-MS-TOF.

Linke T, Scholten M, Baniahmad A.

Methods Mol Biol. 2011;776:225-51. doi: 10.1007/978-1-61779-243-4_14.

PMID:
21796530
30.

Analysis of ligand-specific co-repressor binding to the androgen receptor.

Gerlach C, Roell D, Baniahmad A.

Methods Mol Biol. 2011;776:199-223. doi: 10.1007/978-1-61779-243-4_13.

PMID:
21796529
31.

Androgen receptor-mediated gene repression.

Grosse A, Bartsch S, Baniahmad A.

Mol Cell Endocrinol. 2012 Apr 16;352(1-2):46-56. doi: 10.1016/j.mce.2011.06.032. Epub 2011 Jul 19. Review.

PMID:
21784131
32.

The ING tumor suppressors in cellular senescence and chromatin.

Ludwig S, Klitzsch A, Baniahmad A.

Cell Biosci. 2011 Jul 18;1(1):25. doi: 10.1186/2045-3701-1-25.

33.

BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.

Hentschel J, Rubio I, Eberhart M, Hipler C, Schiefner J, Schubert K, Loncarevic IF, Wittig U, Baniahmad A, von Eggeling F.

Int J Oncol. 2011 Sep;39(3):585-91. doi: 10.3892/ijo.2011.1062. Epub 2011 Jun 1.

PMID:
21637917
34.

A designed cell-permeable aptamer-based corepressor peptide is highly specific for the androgen receptor and inhibits prostate cancer cell growth in a vector-free mode.

Reeb CA, Gerlach C, Heinssmann M, Prade I, Ceraline J, Roediger J, Roell D, Baniahmad A.

Endocrinology. 2011 Jun;152(6):2174-83. doi: 10.1210/en.2011-0149. Epub 2011 Apr 12.

PMID:
21486935
35.

Antiandrogenic activity of anthranilic acid ester derivatives as novel lead structures to inhibit prostate cancer cell proliferation.

Roell D, Rösler TW, Degen S, Matusch R, Baniahmad A.

Chem Biol Drug Des. 2011 Jun;77(6):450-9. doi: 10.1111/j.1747-0285.2011.01116.x. Epub 2011 Apr 27.

PMID:
21439024
36.

The corepressor Alien as a novel tumor suppressor?

Baniahmad A.

Horm Mol Biol Clin Investig. 2011 Mar 1;5(1):11-5. doi: 10.1515/HMBCI.2010.074.

PMID:
25961239
37.

The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth.

Roell D, Baniahmad A.

Mol Cell Endocrinol. 2011 Jan 30;332(1-2):1-8. doi: 10.1016/j.mce.2010.09.013. Epub 2010 Oct 19. Review.

PMID:
20965230
38.

Sirtuin family: a link to metabolic signaling and senescence.

Kyrylenko S, Baniahmad A.

Curr Med Chem. 2010;17(26):2921-32. Review.

PMID:
20858173
39.

20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.

Fousteris MA, Schubert U, Roell D, Roediger J, Bailis N, Nikolaropoulos SS, Baniahmad A, Giannis A.

Bioorg Med Chem. 2010 Oct 1;18(19):6960-9. doi: 10.1016/j.bmc.2010.08.029. Epub 2010 Aug 19.

PMID:
20826091
40.

NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth.

Papaioannou M, Schleich S, Roell D, Schubert U, Tanner T, Claessens F, Matusch R, Baniahmad A.

Invest New Drugs. 2010 Dec;28(6):729-43. doi: 10.1007/s10637-009-9304-y. Epub 2009 Sep 23.

PMID:
19771394
41.

Bag-1M inhibits the transactivation of the glucocorticoid receptor via recruitment of corepressors.

Hong W, Baniahmad A, Li J, Chang C, Gao W, Liu Y.

FEBS Lett. 2009 Aug 6;583(15):2451-6. doi: 10.1016/j.febslet.2009.07.010. Epub 2009 Jul 15.

42.

Regulation of the anaphase-promoting complex by the COP9 signalosome.

Kob R, Kelm J, Posorski N, Baniahmad A, von Eggeling F, Melle C.

Cell Cycle. 2009 Jul 1;8(13):2041-9. Epub 2009 Jul 27.

PMID:
19535905
43.

Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.

Eisold M, Asim M, Eskelinen H, Linke T, Baniahmad A.

J Mol Endocrinol. 2009 May;42(5):429-35. doi: 10.1677/JME-08-0084. Epub 2009 Feb 17.

PMID:
19223455
44.

Bag-1M is a component of the in vivo DNA-glucocorticoid receptor complex at hormone-regulated promoter.

Hong W, Baniahmad A, Liu Y, Li H.

J Mol Biol. 2008 Dec 5;384(1):22-30. doi: 10.1016/j.jmb.2008.09.010. Epub 2008 Sep 16.

PMID:
18822299
45.

Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures.

Söderholm AA, Viiliäinen J, Lehtovuori PT, Eskelinen H, Roell D, Baniahmad A, Nyrönen TH.

J Chem Inf Model. 2008 Sep;48(9):1882-90. doi: 10.1021/ci800149w. Epub 2008 Aug 20.

PMID:
18712859
46.

The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth.

Papaioannou M, Schleich S, Prade I, Degen S, Roell D, Schubert U, Tanner T, Claessens F, Matusch R, Baniahmad A.

J Cell Mol Med. 2009 Aug;13(8B):2210-23. doi: 10.1111/j.1582-4934.2008.00426.x.

47.

ING2 recruits histone methyltransferase activity with methylation site specificity distinct from histone H3 lysines 4 and 9.

Goeman F, Otto K, Kyrylenko S, Schmidt O, Baniahmad A.

Biochim Biophys Acta. 2008 Oct;1783(10):1673-80. doi: 10.1016/j.bbamcr.2008.04.019. Epub 2008 May 10.

48.

Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells.

Asim M, Siddiqui IA, Hafeez BB, Baniahmad A, Mukhtar H.

Oncogene. 2008 Jun 5;27(25):3596-604. doi: 10.1038/sj.onc.1211016. Epub 2008 Jan 28.

PMID:
18223692
49.

The coregulator Alien.

Papaioannou M, Melle C, Baniahmad A.

Nucl Recept Signal. 2007 Nov 30;5:e008. doi: 10.1621/nrs.05008. Review.

50.

Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development.

Moehren U, Papaioannou M, Reeb CA, Grasselli A, Nanni S, Asim M, Roell D, Prade I, Farsetti A, Baniahmad A.

FASEB J. 2008 Apr;22(4):1258-67. Epub 2007 Nov 8.

PMID:
17991730

Supplemental Content

Loading ...
Support Center